Abstracts

NEUROCOGNITIVE AND VOLUMETRIC CHANGES AFTER 24 WEEKS OF DTG/3TC/ABC DISCONTINUATION

Dolutegravir/lamivudine/abacavir (DTG/3TC/ABC) fixed dose combination (FDC) discontinuation is associated with improvement of neuropsychiatric (NP) symptoms. However, limited data exist on the effect of DTG/3TC/ABC discontinuation on neurocognitive (NC) function and brain structure. We assessed NC function and neuroimaging in participants enrolled in the DREAM study, a multicenter clinical trial designed to evaluate the reversibility of…